Fosamax and Osteonecrosis of the Jaw: Scientific Evidence of Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health to Specific Risks

The legacy of general health and science information has long provided a foundation for understanding broad physiological processes and therapeutic interventions. Within this context, the salivary glands have been studied primarily in relation to conditions such as infections, inflammatory disorders like Sjögren’s syndrome, and treatment options for drooling, including medications and surgical approaches. This established knowledge base serves as a critical starting point for examining more specific clinical scenarios. Transitioning from this general framework, attention now turns to the domain of mass production and occupational exposure. In industrial and manufacturing settings, workers may encounter a range of chemical agents and pharmaceuticals, including bisphosphonates such as Fosamax. The potential for exposure in these environments raises questions about associated health risks, particularly concerning the jaw. Scientific inquiry has explored the connection between Fosamax and osteonecrosis of the jaw, focusing on how exposure—whether through direct handling or environmental contamination—may contribute to this condition. This pivot from general health principles to occupational exposure concerns allows for a focused examination of risk factors without delving into disease-specific mechanisms. The transition underscores the importance of bridging broad scientific understanding with targeted investigations into workplace hazards, thereby informing preventive strategies and safety protocols.

Fosamax: Mechanism and Approved Uses

Fosamax (alendronate) is a bisphosphonate medication indicated for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The drug works by inhibiting bone resorption, thereby increasing bone mass and reducing fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a serious adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw (ONJ).

Osteonecrosis of the Jaw: Clinical Presentation and Diagnosis

Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. It can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation often involves pain, swelling, and exposed bone in the jaw, which may persist for weeks to months. Diagnosis is typically based on clinical examination and imaging, with a history of bisphosphonate use being a key consideration.

Scientific Evidence Linking Fosamax to ONJ

The scientific evidence connecting Fosamax to ONJ is supported by multiple lines of investigation. Mechanistically, bisphosphonates like alendronate accumulate in bone tissue, particularly in areas of high turnover such as the jaw. This accumulation can suppress bone remodeling, impair blood supply, and reduce the ability of the jawbone to heal after minor trauma or infection. A multiscale characterization of jawbone in estrogen-deficient rats treated with alendronate found that bisphosphonate treatment affects jawbone properties, including tissue mineral density distribution and mechanical stability of teeth in the alveolar socket (https://pubmed.ncbi.nlm.nih.gov/40345077/). These findings help explain why the jawbone may be particularly susceptible to complications such as ONJ when exposed to bisphosphonates.

Risk Factors and Duration of Exposure

The risk of ONJ is not uniform across all patients. Known risk factors include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Warnings and Causation Considerations

Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This section notes that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and describes associated risk factors. However, the time to onset of symptoms can vary from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a recognized risk, its incidence in clinical trials was not significantly elevated compared to placebo, possibly due to the rarity of the event or differences in study populations. For affected patients, causation-related considerations are complex. The development of ONJ in a patient taking Fosamax does not automatically imply causation, as ONJ can occur spontaneously or due to other factors. However, the temporal relationship between drug exposure and the onset of symptoms is a key factor. The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, and a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This pattern supports a causal relationship in some cases.

Timeline and Management

The timeline between exposure and documented harm can vary widely. ONJ may develop within months of starting Fosamax, but it can also occur after years of use. The risk may increase with longer duration of exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients who develop ONJ, management typically involves discontinuation of the bisphosphonate, good oral hygiene, and possibly surgical debridement. The prescribing information advises discontinuing use if severe symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In summary, the scientific evidence establishes a plausible mechanistic link between Fosamax and ONJ, supported by clinical reports and preclinical studies. The risk is influenced by patient-specific factors and duration of exposure. While warnings are included in the drug labeling, the variability in onset and the rarity of the event in clinical trials highlight the need for continued vigilance and patient education.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how does it work?

Fosamax (alendronate) is a bisphosphonate medication used to treat and prevent osteoporosis, increase bone mass in men with osteoporosis, treat glucocorticoid-induced osteoporosis, and treat Paget's disease of bone. It works by inhibiting bone resorption, thereby increasing bone mass and reducing fracture incidence (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What is osteonecrosis of the jaw (ONJ) and how is it diagnosed?

Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region, often associated with tooth extraction or local infection. Diagnosis is based on clinical examination and imaging, with a history of bisphosphonate use being a key consideration (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What is the scientific evidence linking Fosamax to ONJ?

Mechanistically, bisphosphonates like alendronate accumulate in bone tissue, particularly in the jaw, suppressing bone remodeling and impairing healing. Preclinical studies, such as a multiscale characterization of jawbone in rats, show that alendronate affects jawbone properties (https://pubmed.ncbi.nlm.nih.gov/40345077/). Clinical reports also support a causal relationship, with symptom relief upon discontinuation and recurrence upon rechallenge (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures, cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and pre-existing dental disease. The risk may increase with longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How is ONJ managed in patients taking Fosamax?

Management typically involves discontinuing the bisphosphonate, maintaining good oral hygiene, and possibly surgical debridement. The prescribing information advises discontinuing use if severe symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.